Commercial-stage biotechnology company Krystal Biotech Inc (NASDAQ:KRYS) announced on Tuesday that the US Food and Drug Administration (FDA) has granted Fast Track designation for inhaled KB707 to treat solid tumours with pulmonary metastases that are relapsed or refractory to standard therapy.
KB707, a modified HSV-1 vector designed to deliver interleukin-12 and interleukin-2 genes to the tumour microenvironment, aims to promote immune-mediated tumour clearance.
In January 2024 the FDA cleared the Investigational New Drug (IND) application for Phase 1 clinical trial KYANITE-1, set to commence in the first half of 2024, targeting patients with locally advanced or metastatic solid tumours of the lung.
This is the second Fast Track for KB707, following the FDA's previous approval for intratumoral KB707 in melanoma treatment.
Regeneron and Sanofi's Dupixent gains EU approval for uncontrolled COPD with eosinophilia
INOVIO names new chief commercial officer
Carisma Therapeutics names new directors
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
Biophytis signs Latin American deal with Blanver for BIO101 (20-Hydroxyecdysone)
Natera unveils enhanced Prospera Heart test for transplant patients
Biophytis reports industrial scale production of DMD drug candidate BIO101
EMA grants orphan drug designation to Moleculin's Annamycin for AML
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
ProAxsis secures GBP1.8m investment
CareDx highlights cardiothoracic advancements at ISHLT meeting